Fresh Tracks Therapeutics (OTCPK:FRTX) - Hisse Senedi Fiyatı, Haberler ve Analizler

Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

FRTX Stoklara Genel Bakış

Fresh Tracks Therapeutics, Inc. önemli faaliyetlere sahip değildir.

FRTX temel anali̇z
Kar Tanesi Skoru
Değerleme	2/6
Gelecekteki Büyüme	0/6
Geçmiş Performans	0/6
Finansal Sağlık	4/6
Temettüler	0/6

Ödüller

Risk Analizi

Earnings have declined by 5.8% per year over past 5 years

Does not have a meaningful market cap ($4M)

Son mali raporlar 6 aydan daha eskidir

Fresh Tracks Therapeutics, Inc. Rakipler

Scorpius Holdings

NYSEAM:SCPX

US$2.2m

Sunshine Biopharma

NasdaqCM:SBFM

US$3.6m

Xenetic Biosciences

NasdaqCM:XBIO

US$6.7m

AquaBounty Technologies

NasdaqCM:AQB

US$4.7m

Fiyat Geçmişi ve Performans

için tüm zamanların en yüksek seviyelerinin, değişikliklerin ve fiyat düşüşlerinin özeti Fresh Tracks Therapeutics
Tarihsel hisse senedi fiyatları
Güncel Hisse Fiyatı	US$0.73
52 Haftanın En Yüksek Seviyesi	US$1.04
52 Haftanın En Düşük Seviyesi	US$0.55
Beta	0.47
11 Aylık Değişim	-8.75%
3 Aylık Değişim	-21.45%
1 Yıllık Değişim	-24.43%
33 Yıllık Değişim	-97.64%
5 Yıllık Değişim	-99.62%
Halka arzdan bu yana değişim	-99.65%

Son Haberler & Güncellemeler

Recent updates

Brickell Biotech changes name to Fresh Tracks Therapeutics

Sep 07

Brickell Biotech GAAP EPS of -$0.01 beats by $1.43, revenue of $4.32M beats by $1.18M

Aug 11

Brickell Biotech completes patient enrollment in late-stage sweat disorder study

Apr 27

Brickell Biotech's(NASDAQ:BBI) Share Price Is Down 16% Over The Past Year.

Jan 06

Brickell Biotech (BBI) Investor Presentation - Slideshow

Dec 02

Brickell Bio to launch sofpironium bromide gel, 5% in Japan on November 26

Nov 18

Hissedar Getirileri

	FRTX	US Biotechs	US Pazar
7D	-2.7%	-0.2%	-0.4%
1Y	-24.4%	22.1%	34.1%

Getiri vs. Endüstri: FRTX underperformed the US Biotechs industry which returned 21.7% over the past year.

Getiri vs Piyasa: FRTX underperformed the US Market which returned 33.4% over the past year.

Fiyat Oynaklığı

Is FRTX's price volatile compared to industry and market?
FRTX volatility
FRTX Average Weekly Movement	8.8%
Biotechs Industry Average Movement	10.0%
Market Average Movement	6.4%
10% most volatile stocks in US Market	14.9%
10% least volatile stocks in US Market	3.1%

İstikrarlı Hisse Senedi Fiyatı: FRTX's share price has been volatile over the past 3 months.

Zaman İçindeki Volatilite: FRTX's weekly volatility (9%) has been stable over the past year.

Şirket Hakkında

Kuruldu	Çalışanlar	CEO	Web sitesi
2009	4	Bert Marchio	ir.frtx.com

Fresh Tracks Therapeutics, Inc. önemli faaliyetlere sahip değildir. Daha önce şirket, Amerika Birleşik Devletleri'nde otoimmün, enflamatuar ve diğer zayıflatıcı hastalıkların tedavisi için çeşitli reçeteli terapötiklerin geliştirilmesiyle uğraşıyordu. Fresh Tracks Therapeutics, Inc. 2009 yılında kurulmuştur ve merkezi Boulder, Colorado'dadır.

Fresh Tracks Therapeutics, Inc. Temel Bilgiler Özeti

Fresh Tracks Therapeutics'un kazançları ve gelirleri piyasa değeriyle nasıl karşılaştırılır?
FRTX temel i̇stati̇sti̇kler
Piyasa değeri	US$4.36m
Kazançlar(TTM)	-US$5.69m
Gelir(TTM)	US$8.01m

0.5x

P/S Oranı

-0.8x

F/K Oranı

FRTX aşırı değerli mi?

Gerçeğe Uygun Değer ve değerleme analizine bakınız

Kazanç ve Gelir

En son kazanç raporundan temel karlılık istatistikleri (TTM)
FRTX gelir tablosu (TTM)
Gelir	US$8.01m
Gelir Maliyeti	US$3.18m
Brüt Kâr	US$4.82m
Diğer Giderler	US$10.52m
Kazançlar	-US$5.69m

Son Raporlanan Kazançlar

Dec 31, 2023

Sonraki Kazanç Tarihi

n/a

Hisse başına kazanç (EPS)	-0.95
Brüt Marj	60.25%
Net Kâr Marjı	-71.12%
Borç/Özkaynak Oranı	0%

FRTX uzun vadede nasıl bir performans gösterdi?

Geçmiş performansı ve karşılaştırmayı görün

FRTX Stoklara Genel Bakış

Ödüller

Risk Analizi

Fresh Tracks Therapeutics, Inc. Rakipler

NYSEAM:SCPX

US$2.2m

NasdaqCM:SBFM

US$3.6m

NasdaqCM:XBIO

US$6.7m

NasdaqCM:AQB

US$4.7m

Fiyat Geçmişi ve Performans

Son Haberler & Güncellemeler

Fresh Tracks Therapeutics, Inc. Files Form 15

Fresh Tracks Therapeutics, Inc.(OTCPK:FRTX) dropped from S&P TMI Index

Fresh Tracks Therapeutics, Inc.(OTCPK:FRTX) dropped from NASDAQ Composite Index

Fresh Tracks Therapeutics Announces Its Common Stock to Be Suspended from Trading on Nasdaq At Open of Business on December 19, 2023

Fresh Tracks Therapeutics' Common Stock To Be Delisted from Nasdaq

Fresh Tracks Therapeutics' Common Stock To Be Delisted from Nasdaq

Recent updates

Fresh Tracks Therapeutics, Inc. Files Form 15

Fresh Tracks Therapeutics, Inc.(OTCPK:FRTX) dropped from S&P TMI Index

Fresh Tracks Therapeutics, Inc.(OTCPK:FRTX) dropped from NASDAQ Composite Index

Fresh Tracks Therapeutics Announces Its Common Stock to Be Suspended from Trading on Nasdaq At Open of Business on December 19, 2023

Fresh Tracks Therapeutics' Common Stock To Be Delisted from Nasdaq

Fresh Tracks Therapeutics' Common Stock To Be Delisted from Nasdaq

Fresh Tracks Therapeutics, Inc. Announces Executive Changes

New minor risk - Revenue size

Second quarter 2023 earnings released: US$0.39 loss per share (vs US$0.43 loss in 2Q 2022)

Fresh Tracks Therapeutics, Inc. Announces Resignation of Robert B. Brown from the Board of Directors, Effective Immediately

First quarter 2023 earnings released: US$1.14 loss per share (vs US$3.55 loss in 1Q 2022)

Full year 2022 earnings released: US$7.52 loss per share (vs US$22.12 loss in FY 2021)

Fresh Tracks Therapeutics, Inc. Announces Executive Changes, Effective February 1, 2023

Fresh Tracks Therapeutics, Inc. Announces Publication of Preclinical Data for FRTX-02

Price target increased to US$72.50

Consensus forecasts updated

Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Insufficient new directors

Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Fresh Tracks Therapeutics, Inc. to Report Q3, 2022 Results on Nov 10, 2022

Consensus estimates of losses per share improve by 25%

Fresh Tracks Therapeutics Appoints Deepak Chadha to the Additional Position of Chief Operating Officer

Fresh Tracks Therapeutics Initiates Multiple Ascending Dose Portion of Phase 1 Study of Dyrk1a Inhibitor FRTX-02

Brickell Biotech changes name to Fresh Tracks Therapeutics

Insufficient new directors

Brickell Biotech Receives Notice from the Nasdaq Stock Market in Relation to Non-Compliance with the Independent Director and Audit Committee Requirements

Consensus revenue estimates increase by 26%

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Brickell Biotech GAAP EPS of -$0.01 beats by $1.43, revenue of $4.32M beats by $1.18M

Brickell Biotech, Inc. to Report Q2, 2022 Results on Aug 11, 2022

Brickell Biotech, Inc. Announces Resignation of Dennison T. Veru from the Board of Directors

Brickell Biotech Regains Compliance with Nasdaq Minimum Bid Price Requirement

Brickell Biotech regains Nasdaq compliance for minimum bid price requirement

Brickell Biotech Receives a Notice from the Listing Qualifications Department of the Nasdaq Stock Market

Brickell Biotech, Inc. Announces Executive Changes

Brickell Biotech Doses First Subject in Phase 1 Study of DYRK1A Inhibitor BBI-02

Consensus revenue estimates increase by 159%

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Brickell Biotech, Inc. to Report Q1, 2022 Results on May 12, 2022

Consensus revenue estimates fall by 47%

Price target decreased to US$2.67

Full year 2021 earnings: EPS and revenues miss analyst expectations

Here's Why Brickell Biotech (NASDAQ:BBI) Must Use Its Cash Wisely

Third quarter 2021 earnings released: US$0.16 loss per share (vs US$0.15 loss in 3Q 2020)

Second quarter 2021 earnings released: US$0.16 loss per share (vs US$0.43 loss in 2Q 2020)

Co-Founder & Chairman of the Board recently bought US$134k worth of stock

Brickell Biotech, Inc. has completed a Follow-on Equity Offering in the amount of $7 million.

Brickell Biotech, Inc. Announces Final Patient Completed in First U.S. Phase 3 Pivotal Clinical Study and Patient Enrollment Completed in Second U.S. Phase 3 Pivotal Clinical Study of Sofpironium Bromide Gel, 15% for the Treatment of Primary Axillary Hyperhidrosis

Brickell Biotech Announces Initiation of A Phase 1 Study of Sofpironium Bromide Gel in Primary Palmoplantar Hyperhidrosis Patients by Its Development Partner, Kaken Pharmaceutical in Japan

Brickell Biotech Receives A Notice from Listing Qualifications Department of Nasdaq Stock Market

Brickell Biotech, Inc. Announces Publication of Japan Phase 3 Long-Term Safety and Efficacy Study Results for Sofpironium Bromide Gel, 5% (ECCLOCK®) in the Journal of Dermatology

First quarter 2021 earnings released: US$0.15 loss per share (vs US$0.45 loss in 1Q 2020)

Brickell Biotech Advances To Phase III As It Eyes Commercialization

Brickell Biotech Completes Patient Enrollment in U.S. Phase 3 Pivotal Cardigan I Study of Sofpironium Bromide Gel, 15% for the Treatment of Primary Axillary Hyperhidrosis

Brickell Biotech completes patient enrollment in late-stage sweat disorder study

CEO & Director recently bought US$118k worth of stock

Brickell Biotech, Inc., Annual General Meeting, Apr 19, 2021

Full year 2020 earnings released: US$0.85 loss per share (vs US$4.50 loss in FY 2019)

Earnings beat expectations, revenue disappoints